SCCHN clinical trials at University of California Health

1 in progress, 0 open to eligible people

Showing trials for

  • XB002 in Subjects With Solid Tumors (JEWEL-101)

    Sorry, in progress, not accepting new patients

    This is a Phase 1, open-label, multicenter, dose-escalation and expansion study evaluating the safety, tolerability, PK, pharmacodynamics, and clinical antitumor activity of XB002 administered IV q3w alone and in combination with nivolumab to subjects with advanced solid tumors.

    at UCLA

Our lead scientists for SCCHN research studies include .

Last updated: